What does Sativex stand for?
Sativex: Nabiximols
An oromucosal spray containing THC (2.7mg) and CBD (2.5mg) per spray in a 1:1 ratio. The only licensed cannabis-based medicine for MS-related spasticity in the UK. NHS-funded for qualifying MS patients who pass an initial trial.
Where you will see it
In the guides to NHS funding.
NHS and privateRelated terms
- CBD (Cannabidiol)
The second most studied cannabinoid. Non-intoxicating. Has anti-inflammatory, anxiolytic, anticonvulsant, and analgesic properties. Used in Epidyolex (licensed for epilepsy) and as a component in many unlicensed CBPMs.
- THC (Tetrahydrocannabinol)
The primary psychoactive compound in cannabis. Responsible for the "high" associated with recreational use. At controlled therapeutic doses, THC has analgesic, antiemetic, muscle-relaxant, and sleep-promoting effects. The main active compound in most CBPM flower and high-THC oil prescriptions.
- CINV (Chemotherapy-Induced Nausea and Vomiting)
Nausea and vomiting caused by cancer chemotherapy. A well-evidenced indication for cannabinoid medicines including nabilone.
- Dravet Syndrome
A severe form of epilepsy beginning in infancy, associated with frequent and prolonged seizures. Epidyolex (CBD oral solution) is NICE-approved and NHS-funded for this condition.
- Epidyolex
A pharmaceutical-grade CBD oral solution. The only fully licensed cannabis-based medicine in the UK with NICE approval. Indicated for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged 2 and above. NHS-funded.
This is a plain-language definition for general understanding, not medical or legal advice.
All 101 terms